Valuation: Pacific Software, Inc.

Market Cap 48.82M 43.78M 40.35M 36.65M 69.35M 4.58B 71.29M 483M 192M 2.45B 183M 179M 7.75B P/E 2019
-2.65x
P/E 2020 -41.2x
Enterprise Value 49.19M 44.11M 40.65M 36.92M 69.88M 4.61B 71.83M 487M 194M 2.47B 185M 181M 7.81B EV / Sales 2019
-
EV / Sales 2020 2,435,972,350x
Free-Float
64%
Yield 2019 *
-
Yield 2020 -
1 day-33.33%
1 week-38.78%
Current month-25.00%
1 month-40.00%
3 months-45.45%
6 months-25.00%
Current year-75.00%
1 week 0.02
Extreme 0.025
0.04
1 month 0.02
Extreme 0.025
0.06
Current year 0.01
Extreme 0.0088
0.09
1 year 0.01
Extreme 0.0088
0.12
3 years 0
Extreme 0.001
0.3
5 years 0
Extreme 0.001
2.37
10 years 0
Extreme 0.001
5.59
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 10/06/2026
Director TitleAgeSince
Chairman 74 22/10/2016
Change 5-day change 1-year change 3-year change Capi.($)
-33.33%-38.78%-40.00%-70.00% 2.81M
+0.01%+8.40%+58.48%+69.01% 68.22B
+1.22%+9.56%+15.97%+90.23% 59.82B
+0.24%+1.35%+23.78%+97.55% 56.07B
+0.90%+18.51%+27.80%+111.30% 47.67B
-1.08%+4.92%+29.31%+40.58% 45.95B
-4.23%-1.16%+206.05%+874.05% 43.29B
-3.33%+5.73%+23.28%+47.32% 35.66B
-2.19%-3.71%+90.94%+66.33% 34.73B
+2.05%+13.22%-38.39%+397.89% 25.47B
Average -3.98%+4.81%+39.72%+172.42% 42B
Weighted average by Cap. -0.62%+5.40%+50.09%+179.21%

Financials

2019 2020
Net sales - 0.02 0.02 0.02 0.02 0.03 1.88 0.03 0.2 0.08 1 0.08 0.07 3.18
Net income -21.11M -18.93M -17.45M -15.85M -29.99M -1.98B -30.83M -209M -83.24M -1.06B -79.23M -77.55M -3.35B -1.17M -1.05M -971K -881K -1.67M -110M -1.71M -11.62M -4.63M -58.99M -4.41M -4.31M -186M
Net Debt -101K -90.18K -83.11K -75.48K -143K -9.43M -147K -995K -396K -5.05M -377K -369K -15.97M 367K 330K 304K 276K 522K 34.45M 537K 3.64M 1.45M 18.46M 1.38M 1.35M 58.35M
Logo Pacific Software, Inc.
PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.
Employees
2
Date Price Change Volume
10/11/26 $0.0300 -33.33% 484,160
09/11/26 $0.0450 0.00% 3,000
06/11/26 $0.0450 0.00% 3,000
05/11/26 $0.0450 +12.50% 1,200
04/11/26 $0.0400 -18.37% 50,000
  1. Stock Market
  2. Stocks
  3. PFSF Stock